3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Classical hematology
1
Conditions
Tourette Syndrome
1
Stress Disorders, Post-Traumatic
1
Sleep Initiation and Maintenance Disorders
1
Severe Acute Respiratory Syndrome
1
Seizures
1
Parkinson Disease
1
Pancreatic Cancer Non-resectable
1
Opioid-Related Disorders
1
Neoplasms
1
Multiple Sclerosis
1
Marijuana Abuse
1
Inflammatory Bowel Diseases
1
Hepatitis C
1
Glaucoma
1
Fibromyalgia
1
Epilepsy
1
Depression
1
Crohn Disease
1
Coronavirus Infections
1
Colitis, Ulcerative
1
Chronic Traumatic Encephalopathy
1
Chronic Pain
1
Carcinoma, Hepatocellular
1
COVID-19
1
Brain Injuries, Traumatic
1
Bipolar Disorder
1
Autistic Disorder
1
Anxiety Disorders
1
Anemia, Sickle Cell
1
Amyotrophic Lateral Sclerosis
1
Interventions
Doxorubicin
5
Filgrastim
4
Zidovudine
3
Vincristine
3
Etoposide
3
Valganciclovir
2
Thalidomide
2
Rituximab
2
Mitoxantrone
2
Interferon alpha-2
2
Cyclophosphamide
2
Bleomycin
2
ziconotide
1
vesnarinone
1
tocilizumab
1
tin etiopurpurin
1
interferon gamma-1b
1
human papillomavirus vaccine, L1 type 16, 18
1
Vinblastine
1
Tumor Necrosis Factor-alpha
1
Sugars
1
Semaxinib
1
Ro 24-7429
1
Ritonavir
1
Prednisone
1
Paclitaxel
1
Nivolumab
1
Mitoguazone
1
Methotrexate
1
Medical Marijuana
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Acquired Immunodeficiency Syndrome
×
Medical Marijuana
×
Clear all
NCT03944447
2022-06-02
OMNI-Can
OMNI Medical Services, LLC
Phase 2
Unknown
200,000 enrolled